Activating the Drug Discovery Platform through Open Innovation and New Technologies

「The Company is taking on the challenge of drug discovery innovation that creates new clinical value by combining the diversification of its drug discovery platform with disease research in sophisticated ways.」

「In addition to pursuing drug discovery based on novel mechanisms of action identified through disease research, the Company is working on drug discovery that creates new value through innovative technologies. It also actively approached external organizations to use innovative technologies, including nucleic acid drug discovery, in addition to the small-molecule drug discovery on which it has focused to date. In terms of research areas, the Company decided to focus its drug discovery research on 3 areas: pulmonary fibrosis, pain and autoimmune diseases.」

「In addition to drug discovery based on novel mechanisms of action identified through disease research, the Company is pursuing drug discovery that creates new value through innovative technologies. It is strengthening its drug discovery platform by actively promoting the use of nucleic acid drug discovery and innovative external technologies as new modalities, in addition to the small-molecule drug discovery on which it has focused to date」

「We are strengthening our drug discovery platform by actively expanding the use of nucleic acid drug discovery and innovative external technologies as new modalities in addition to the small-molecule drug discovery on which we have focused to date, and are pursuing drug discovery innovation to create high-value new drugs by combining these efforts with disease research.」

「We are strengthening our drug discovery platform by actively expanding the use of nucleic acid drug discovery and innovative external technologies as new modalities in addition to the small-molecule drug discovery on which we have focused to date, and are pursuing drug discovery innovation to create high-value new drugs by combining these efforts with disease research.」

「Kyorin Pharmaceutical Co., Ltd. worked to activate its drug discovery platform by adding open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to in-house drug discovery, while also working to apply and develop new technologies such as nucleic acids.」

「Kyorin Pharmaceutical Co., Ltd. worked to activate its drug discovery platform by adding open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to in-house drug discovery, while also working to apply and develop new technologies such as nucleic acids and peptides.」

「Kyorin Pharmaceutical Co., Ltd. worked to activate its drug discovery platform by adding open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to in-house drug discovery, while also working to apply and develop new technologies such as nucleic acids and peptides.」

「We actively explored and considered the introduction of external drug discovery programs and developed initiatives aimed at first-in-class drug discovery.」

「By adding open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to in-house drug discovery, the Company is working to revitalize its drug discovery platform while also applying and developing new technologies, including nucleic acids and peptides.」

「The Company is also pursuing activities aimed at first-in-class drug discovery by actively searching for and introducing external drug discovery programs.」

「In addition to further revitalizing its existing drug discovery platform, the Company worked to apply and develop new technologies, including nucleic acids, peptides and gene therapy.」

「In December of the same year, the Company entered into a strategic partnership with Yissum, the technology transfer company of the Hebrew University of Jerusalem, to develop therapeutic drugs for diseases in the respiratory field.」

「In drug discovery research, as part of our open innovation activities, we entered into a strategic partnership with Yissum, the technology transfer company of the Hebrew University of Jerusalem, in December 2018 for the creation of therapeutics for respiratory diseases.」

「As part of its open innovation initiatives in drug discovery research, 杏林製薬㈱ also launched joint research during the current fiscal year with the Institute of Microbial Chemistry, Microbial Chemistry Research Foundation. The aim is to strengthen the Group's drug discovery capabilities in infectious diseases, one of its priority research areas.」

「We will continue to make steady progress toward first-in-class drug discovery by further focusing and prioritizing our drug discovery themes, pursuing development of multilayered programs, and actively exploring and in-licensing external drug discovery themes.」

「By adding open innovation with domestic and overseas pharmaceutical companies, academia and venture companies to in-house drug discovery by the Watarase Drug Discovery Center and ActivX, the Company worked to revitalize its existing drug discovery platform and apply new technologies, including peptides and gene therapy.」

「By combining Kyoto University's capabilities in disease research, including organ fibrosis processes such as pulmonary fibrosis, and basic research, including the application of technology platforms using iPS cells, with 杏林製薬㈱'s drug discovery capabilities, the Company aims to identify disease factors in respiratory diseases and investigate their potential as drug discovery targets, leading to the creation of novel drug discovery targets and the identification of small-molecule compound candidates.」

「As part of its open innovation initiatives, the Company established a joint research program with Kyoto University in April 2017 and began collaborative research. By combining Kyoto University's capabilities in disease research, including organ fibrosis processes such as pulmonary fibrosis, and basic research, including the application of technology platforms using iPS cells, with 杏林製薬㈱'s drug discovery capabilities, the Company aims to identify disease factors in respiratory diseases and investigate their potential as drug discovery targets, leading to the creation of novel drug discovery targets and the identification of small-molecule compound candidates.」

「By combining in-house drug discovery by the Watarase Drug Discovery Center and ActivX with open innovation involving pharmaceutical companies, academia and venture companies in Japan and overseas, we worked to activate our existing drug discovery platform and utilize new technologies such as peptides and gene therapy.」